The new Gold Standard technology from Scisense known as 'Admittance' is now available for use in larger hearts. Previously only available for use with rodents, Scisense is pleased to announce the same benefits now exist for cardiovascular function assessment in all sizes of hearts:
- automatic calibration for ‘parallel conductance’;
• no hypertonic saline bolus injection
• no cuvette calibration
- absolute volume measurement in real-time;
- data comparisons across homogeneous subjects;
- reduced sample sizes and protocol time due to more accurate and consistent data;
A recent TV news clip and an article on the Scisense ADVantage PV loop system can be viewed at kens5.com: "[Dr.] Feldman calls it 'pure biomedical engineering. It's physiologists and physicians, and engineers from two different worlds working together to create an invention that neither one could do alone,' he said." by Wendy Rigby, KENS 5.
The PV loop not only gives the important ventricular pressure-to-volume relationship, but a multitude of other valuable indices of myocardial contractility and hemodynamics.
More information is also available from the company website at scisense.com/products/.
Scisense Inc. (scisense.com) specializes in micro-sensing technologies for use in preclinical research. Products include high-fidelity pressure sensors used to measure blood pressure, PV catheters, and catheters for electrophysiology applications.
The company’s head office and manufacturing facilities are located in London, Ontario, Canada. Since its incorporation in 2002, Scisense has focused on contributing to the advancement of research into cardiac disease and has well established itself as a technology leader. The company employs an expert staff of engineers and scientists, and an extensive network of customers throughout the world at universities, pharmaceutical companies and contract research organizations.